Renaissance Technologies LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,057,598 shares of the biopharmaceutical company's stock after buying an additional 739,948 shares during the period. Gilead Sciences comprises 0.6% of Renaissance Technologies LLC's portfolio, making the stock its 14th largest holding. Renaissance Technologies LLC owned approximately 0.41% of Gilead Sciences worth $347,002,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after buying an additional 2,910,147 shares in the last quarter. Capital World Investors lifted its holdings in shares of Gilead Sciences by 1.4% during the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company's stock valued at $6,189,435,000 after acquiring an additional 1,133,281 shares during the period. Capital Research Global Investors boosted its stake in shares of Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock valued at $4,486,296,000 after purchasing an additional 1,589,240 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company's stock worth $1,509,227,000 after purchasing an additional 2,350,550 shares in the last quarter. Finally, Parnassus Investments LLC lifted its holdings in Gilead Sciences by 0.3% during the 4th quarter. Parnassus Investments LLC now owns 11,952,057 shares of the biopharmaceutical company's stock valued at $968,236,000 after purchasing an additional 36,686 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Trading Up 0.4 %
Shares of GILD stock traded up $0.35 on Monday, reaching $83.16. The company had a trading volume of 7,844,117 shares, compared to its average volume of 7,172,206. The stock has a market cap of $103.53 billion, a PE ratio of 230.14, a PEG ratio of 2.80 and a beta of 0.18. The company has a 50-day moving average of $75.48 and a 200-day moving average of $70.84. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion for the quarter, compared to analysts' expectations of $6.64 billion. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.70%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences's dividend payout ratio is currently 855.56%.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company's stock, valued at $8,506,146.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock worth $3,002,940. 0.16% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
GILD has been the subject of several recent analyst reports. Evercore ISI raised shares of Gilead Sciences to a "strong-buy" rating in a report on Friday, August 9th. Piper Sandler reiterated an "overweight" rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Truist Financial increased their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. Robert W. Baird reiterated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Thursday, June 20th. Finally, Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a "sector perform" rating in a research note on Wednesday, September 4th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $82.06.
Read Our Latest Report on GILD
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
